tetano
Editor, Senior Moderator
Oncotarget. 2017 Sep 20;8(58):98084-98093. doi: 10.18632/oncotarget.21104. eCollection 2017 Nov 17.
[h=1]Evaluation of protective efficacy of three novel H3N2 canine influenza vaccines.[/h] Tu L[SUP]#[/SUP][SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Zhou P[SUP]#[/SUP][SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Li L[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Li X[SUP]1[/SUP], Hu R[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Jia K[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Sun L[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Yuan Z[SUP]1[/SUP], Li S[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Canine influenza virus (CIV) has the potential risk to spread in different areas and dog types. Thus, there is a growing need to develop an effective vaccine to control CIV disease. Here, we developed three vaccine candidates: 1) a recombinant pVAX1 vector expressing H3N2 CIV hemagglutinin (pVAX1-HA); 2) a live attenuated canine adenovirus type 2 expressing H3N2 CIV hemagglutinin (rCAV2-HA); and 3) an inactivated H3N2 CIV (A/canine/Guangdong/01/2006 (H3N2)). Mice received an initial intramuscular immunization that followed two booster injections at 2 and 4 weeks post-vaccination (wpv). The splenic lymphocytes were collected to assess the immune responses at 6 wpv. The protective efficacy was evaluated by challenging H3N2 CIV after vaccination (at 6 wpv). Our results demonstrated that all three vaccine candidates elicited cytokine and antibody responses in mice. The rCAV2-HA vaccine and the inactivated vaccine generated efficient protective efficacy in mice, whereas limited protection was provided by the pVAX1-HA DNA vaccine. Therefore, both the rCAV2-HA live recombinant virus and the inactivated CIV could be used as potential novel vaccines against H3N2CIV. This study provides guidance for choosing the most appropriate vaccine for the prevention and control of CIV disease.
[h=4]KEYWORDS:[/h] H3N2; canine influenza vaccine; inactivated CIV; pVAX1-HA; rCAV2-HA
PMID: 29228675 PMCID: PMC5716715 DOI: 10.18632/oncotarget.21104
[h=1]Evaluation of protective efficacy of three novel H3N2 canine influenza vaccines.[/h] Tu L[SUP]#[/SUP][SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Zhou P[SUP]#[/SUP][SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Li L[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Li X[SUP]1[/SUP], Hu R[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Jia K[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Sun L[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Yuan Z[SUP]1[/SUP], Li S[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Canine influenza virus (CIV) has the potential risk to spread in different areas and dog types. Thus, there is a growing need to develop an effective vaccine to control CIV disease. Here, we developed three vaccine candidates: 1) a recombinant pVAX1 vector expressing H3N2 CIV hemagglutinin (pVAX1-HA); 2) a live attenuated canine adenovirus type 2 expressing H3N2 CIV hemagglutinin (rCAV2-HA); and 3) an inactivated H3N2 CIV (A/canine/Guangdong/01/2006 (H3N2)). Mice received an initial intramuscular immunization that followed two booster injections at 2 and 4 weeks post-vaccination (wpv). The splenic lymphocytes were collected to assess the immune responses at 6 wpv. The protective efficacy was evaluated by challenging H3N2 CIV after vaccination (at 6 wpv). Our results demonstrated that all three vaccine candidates elicited cytokine and antibody responses in mice. The rCAV2-HA vaccine and the inactivated vaccine generated efficient protective efficacy in mice, whereas limited protection was provided by the pVAX1-HA DNA vaccine. Therefore, both the rCAV2-HA live recombinant virus and the inactivated CIV could be used as potential novel vaccines against H3N2CIV. This study provides guidance for choosing the most appropriate vaccine for the prevention and control of CIV disease.
[h=4]KEYWORDS:[/h] H3N2; canine influenza vaccine; inactivated CIV; pVAX1-HA; rCAV2-HA
PMID: 29228675 PMCID: PMC5716715 DOI: 10.18632/oncotarget.21104